• PO (Adults): 4 mg q 4–6 hr or 8–12 mg of extended-release formulation q 8–12 hr (not to exceed 24 mg/day).
CV: Bradycardia; extrasystoles; orthostatic hypotension; palpitations; reflex tachycardia; tachycardia.
CNS: Confusion; convulsions; disturbed coordination; dizziness; drowsiness; euphoria; excitation; faintness; fatigue; headache; hysteria; insomnia; irritability; nervousness; neuritis; paresthesias; restlessness; sedation; tremor; vertigo.
EENT: Acute labyrinthitis; blurred vision; diplopia; dry nose and throat; nasal stuffiness; sore throat; tinnitus.
GI: Anorexia; constipation; diarrhea; dry mouth; epigastric distress; nausea; vomiting.
GU: Difficult urination; dysuria; early menses; urinary frequency or retention.
HEMA: Agranulocytosis; hemolytic anemia; thrombocytopenia.
METAB: Increased appetite; weight gain.
RESP: Chest tightness; respiratory depression; thickening of bronchial secretions; wheezing.
OTHER: Chills; excessive perspiration; hypersensitivity reactions; photosensitivity.
Alcohol, CNS depressants, and tricyclic antidepressants
May cause additive CNS depressant effects.
May increase anticholinergic effects of chlorpheniramine.
Concurrent use may mask the symptoms of ototoxicity.
Therapeutic Classification: allergy, cold and cough remedies, antihistamines
Absorption: Readily absorbed.
Distribution: 72% protein bound.
Metabolism: Metabolized predominantly in the liver, but also in the lung and kidneys.
Excretion: Renally eliminated, mostly as metabolites within 24 h.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal